In this talk, A/Prof Samantha Hocking will bring you up to date on all the latest developments on the GLP1 front. Currently, Trulicity, Saxenda, Ozempic and the most recent addition Mounjaro are the options available in Australia but more are coming over the horizon, including some that are oral rather than injectable. A/Prof Hocking will describe their approved indications, current issues such as shortages of supply and the most recent information about compliance and side effects.

See omnystudio.com/listener for privacy information.